Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  AcelRx Pharmaceuticals Inc    ACRX

ACELRX PHARMACEUTICALS INC (ACRX)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/16/2018 07/17/2018 07/18/2018 07/19/2018 07/20/2018 Date
3.1(c) 3(c) 2.9(c) 2.95(c) 2.95(c) Last
1 060 685 354 944 1 062 789 587 346 289 620 Volume
-3.13% -3.23% -3.33% +1.72% 0.00% Change
More quotes
Financials (USD)
Sales 2018 5,50 M
EBIT 2018 -38,0 M
Net income 2018 -45,3 M
Debt 2018 -
Yield 2018 -
Sales 2019 20,1 M
EBIT 2019 -39,9 M
Net income 2019 -44,8 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 27,5x
Capi. / Sales2019 7,52x
Capitalization 151 M
More Financials
Company
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of acute pain.Its products include DSUVIA and ZALVISO.The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and... 
More about the company
Surperformance© ratings of AcelRx Pharmaceuticals Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ACELRX PHARMACEUTICALS INC
07/20ACELRX PHARMACEUTICALS : Announces Pricing of Public Offering of Common Stock
AQ
07/20ACELRX PHARMACEUTICALS : Announces Commencement of Public Offering of Common Sto..
AQ
07/19ACELRX PHARMACEUTICALS : to announce second quarter 2018 results and provide a c..
PR
07/18Free Technical Research on Medtronic and Three More Medical Equipment Equitie..
AC
07/16ACELRX PHARMACEUTICALS : Announces Pricing of Public Offering of Common Stock
AQ
07/13ACELRX PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (fo..
AQ
07/13ACELRX PHARMACEUTICALS : Announces Commencement of Public Offering of Common Sto..
AQ
07/12ACELRX PHARMACEUTICALS : Announces Pricing of Public Offering of Common Stock
PR
07/11ACELRX PHARMACEUTICALS INC : Results of Operations and Financial Condition (form..
AQ
07/11ACELRX PHARMACEUTICALS : Announces Commencement of Public Offering of Common Sto..
PR
More news
Sector news : Bio Therapeutic Drugs
07/19Novartis, MorphoSys and Galapagos Shares Rise on News of Deal
DJ
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
07/19$ACRX AcelRx to announce second quarter 2018 results and provide a corporate ..
1
07/18Richard King's beach-worthy novel picks!
1
07/18Richard King's non-fiction picks for today! 
07/13After Hours Gainers / Losers (07/13/2018)  
07/13$ACRX New Form 8-K for AcelRx Pharmaceuticals From our Stock News Alerts App 
More tweets
Qtime:132
News from SeekingAlpha
07/20FDA releases updated industry guidelines for development of generic abuse-det.. 
07/19Cheap AcelRx Options Minimize Risk And Maximize Potential Profit 
07/16AcelRX - The Military Angle That Could Boost Its Prospects 
07/13After Hours Gainers / Losers (07/13/2018) 
07/13Premarket analyst action - healthcare 
STOCK PICK
Double or Nothing
Chart ACELRX PHARMACEUTICALS INC
Duration : Period :
AcelRx Pharmaceuticals Inc Technical Analysis Chart | ACRX | US00444T1007 | 4-Traders
Technical analysis trends ACELRX PHARMACEUTICALS INC
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 5,38 $
Spread / Average Target 82%
EPS Revisions
Managers
NameTitle
Stephen J. Hoffman Independent Director
Vincent J. Angotti Chief Executive Officer & Director
Adrian Adams Chairman
Raffi Asadorian CFO & Principal Accounting Officer
Pamela Pierce Palmer Director & Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ACELRX PHARMACEUTICALS INC45.68%151
GILEAD SCIENCES8.00%100 185
VERTEX PHARMACEUTICALS18.38%45 900
REGENERON PHARMACEUTICALS-2.35%38 962
GENMAB9.33%10 874
NEUROCRINE BIOSCIENCES, INC.33.30%9 332